中文版正在生成中，先为你展示英文版分析。
AI核心结论
DexCom delivered a strong Q1 FY2026 with revenue rising 15.0% YoY to $1.19B, gross margin expanding 610 bps to 62.9%, and operating income nearly doubling to $255.3M, reflecting significant operational leverage.
营业收入
$1.19B
同比 ++15.05%
每股收益（基本）
$0.52
同比 ++92.59%
毛利率
62.9%
同比 ++6.10%
营业利润
$255.3M
同比 ++90.95%
提交于 · 解读更新于 · 来源: SEC EDGAR 10-Q 原文
Dexcom (DXCM) Q1 FY2026 营收 $1.19B，同比增长 15.0%。 净利润 $199.5M，同比增长 89.3%，稀释每股收益 $0.51。 毛利率 62.9%。
Revenue grew 15.0% YoY to $1.19B in Q1 FY2026, up from $1.04B in Q1 FY2025, indicating continued strong demand for DexCom's continuous glucose monitoring (CGM) products across its customer base.
来源: Source: 10-Q Income Statement
Gross margin improved significantly to 62.9% from 56.9% in the prior year period, a 610 bps expansion, driven by a 1.2% decline in cost of revenue despite 15% revenue growth — suggesting meaningful manufacturing efficiencies and favorable product mix.
来源: Source: 10-Q Income Statement
Operating income surged 90.9% YoY to $255.3M, with operating margin expanding 850 bps to 21.4% from 12.9%, as R&D expenses remained essentially flat (+0.1% YoY at $145.3M) while revenue scaled substantially.
来源: Source: 10-Q Income Statement
Operating cash flow jumped 186.0% YoY to $525.6M from $183.8M, far outpacing net income growth of 89.3%, reflecting strong working capital management and non-cash add-backs including $67.1M in D&A.
来源: Source: 10-Q Cash Flow Statement
Stockholders' equity rose 30.5% YoY to $3.0B while total liabilities fell 18.0% to $3.68B, and cash & equivalents grew 23.6% to $1.12B, indicating a meaningfully improved financial position and reduced leverage.
来源: Source: 10-Q Balance Sheet
Selling, general & administrative expenses grew 12.8% YoY to $349.7M, representing the largest operating cost line item and outpacing revenue growth on an absolute dollar basis. Sustained increases in SG&A could pressure operating margins if revenue growth moderates. Management will need to demonstrate continued leverage on this cost base.
来源: Source: 10-Q Income Statement
The debt-to-equity ratio stands at 1.24x, indicating that DexCom carries more debt than equity on its balance sheet. While the ratio has improved as equity grew 30.5% YoY, the company remains meaningfully leveraged. Rising interest rates or a revenue slowdown could strain debt servicing capacity.
来源: Source: 10-Q Balance Sheet
Investing cash flow swung sharply to -$298.5M from +$100.2M in the prior year period, a nearly 400% deterioration, suggesting significant capital deployment into investments or capital expenditures. If these investments do not generate expected returns, it could weigh on future free cash flow.
来源: Source: 10-Q Cash Flow Statement
Current liabilities of $2.22B remain elevated relative to current assets of $4.33B, yielding a current ratio of 1.95x. While adequate, the large absolute level of near-term obligations — down 26.8% YoY but still substantial — requires continued strong cash generation to service comfortably.
来源: Source: 10-Q Balance Sheet
DexCom's revenue is concentrated in the continuous glucose monitoring market, making it highly sensitive to competitive dynamics, reimbursement policy changes, and regulatory developments specific to diabetes management devices. Any adverse shift in this niche market could disproportionately impact results.
来源: Source: 10-Q Income Statement
Q1 FY2026 实际 EPS $0.56，分析师一致预期 $0.48，超预期 +17.0%。
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营业收入 | $1.19B | $1.04B | +15.05% |
营业成本 | $441.6M | $447M | -1.21% |
毛利润 | $750.3M | $589M | +27.39% |
营业利润 | $255.3M | $133.7M | +90.95% |
净利润 | $199.5M | $105.4M | +89.28% |
每股收益（基本） | $0.52 | $0.27 | +92.59% |
每股收益（稀释） | $0.51 | $0.27 | +88.89% |
研发费用 | $145.3M | $145.2M | +0.07% |
销售及管理费用 | $349.7M | $310.1M | +12.77% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
总资产 | $6.63B | $6.75B | -1.75% |
流动资产 | $4.33B | $4.55B | -4.88% |
总负债 | $3.68B | $4.49B | -18.03% |
流动负债 | $2.22B | $3.04B | -26.78% |
股东权益 | $2.96B | $2.27B | +30.46% |
现金及等价物 | $1.12B | $904.9M | +23.57% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
经营活动现金流 | $525.6M | $183.8M | +185.96% |
投资活动现金流 | $-298.5M | $100.2M | -397.90% |
筹资活动现金流 | $-25M | $12.5M | -300.00% |
折旧及摊销 | $67.1M | $60M | +11.83% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
毛利率 | 62.9% | 56.9% | +6.10% |
营业利润率 | 21.4% | 12.9% | +8.51% |
净利率 | 16.7% | — | — |
净资产收益率 | 6.7% | — | — |
总资产收益率 | 3.0% | — | — |
流动比率 | $1.948 | — | — |
资产负债率 | $1.243 | — | — |
DexCom had a strong Q1 FY2026, with revenue growing 15.0% YoY to $1.19B and net income nearly doubling to $199.5M. Operating margin expanded significantly to 21.4% from 12.9% a year ago, reflecting strong operational leverage.
DexCom's 15.0% revenue growth to $1.19B in Q1 FY2026 was accompanied by a 1.2% decline in cost of revenue, suggesting both volume growth and improved manufacturing efficiency. The strong gross margin expansion to 62.9% from 56.9% points to favorable product mix and pricing dynamics in its CGM business.
DexCom's financial health improved materially in Q1 FY2026, with cash & equivalents rising 23.6% to $1.12B, stockholders' equity growing 30.5% to $3.0B, and total liabilities declining 18.0% to $3.68B. The current ratio of 1.95x indicates solid short-term liquidity, though the debt-to-equity ratio of 1.24x reflects ongoing leverage.
DexCom generated $525.6M in operating cash flow in Q1 FY2026, a remarkable 186% increase from $183.8M in Q1 FY2025. This strong cash generation significantly exceeded net income of $199.5M, highlighting the high cash-conversion quality of the business.
Key risks for DexCom include its concentrated exposure to the CGM market, which makes it sensitive to competitive and reimbursement changes, as well as SG&A expenses growing 12.8% YoY to $349.7M which could pressure margins if revenue growth slows. The company also carries a debt-to-equity ratio of 1.24x, meaning leverage remains a consideration despite balance sheet improvements.